Wall Street PR
1,051 FOLLOWERS
Wall Street PR is your information partner in the financial markets. It provides you with fresh insights into the financial sector.
Wall Street PR
2M ago
No matter how much most of us would like them too, stocks can’t go straight up forever.
Social media has become a breeding ground for retail investor sentiment, and with it comes a fair share of emotional outbursts. When a stock price dips after a significant run-up, accusations of short selling and dark pool activity are common. That said, it’s crucial to consider a simpler explanation: a healthy pullback.
Imagine this: You buy a stock at $10, and within a month, it skyrockets to $20. Then the stock price dips to $18. Panic sets in, and social media chatter gets louder about potential causes ..read more
Wall Street PR
2M ago
Society Pass Inc. (NASDAQ: SOPA) has announced that it has entered into a structured financing agreement with Strattners FZCO to access capital efficiently. According to the agreement, SoPa can sell its common stock to Strattners worth up to $40,000,000 on SoPa’s request during the next 36 months, subject to certain limitations. The Company plans to use this capital in its operating subsidiaries, including Thoughtful Media Group Inc. and NusaTrip Inc., to invest in acquisitions and strengthen its working capital. The financing strategy will be implemented only when market conditions for SoPa’s ..read more
Wall Street PR
2M ago
We like to focus our research on disruptive new technologies or “angles” on established industries—new opportunities that are all about turning something on its head in a way that offers up the potential to drive serious growth for investors.
Today’s focus stock is Mangoceuticals Inc (NASDAQ:MGRX), makers of the Mango treatment for erectile disfunction. Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance.
The company has noted that it believes the k ..read more
Wall Street PR
2M ago
According to the International Energy Agency (IEA), global investment in fossil fuels fell by 20% in 2020, to $536 billion. This was the lowest level of investment since 2014.
The decline in investment was driven by a number of factors, including the COVID-19 pandemic, which led to a sharp drop in energy demand, and the increasing cost of extraction.
The IEA expects investment in fossil fuels to remain weak in the coming years.
In its World Energy Outlook 2022, the IEA projects that global investment in fossil fuels will average $500 billion per year between 2022 and 2026. This is below the le ..read more
Wall Street PR
2M ago
One company we have covered several times here is Mangoceuticals, Inc. (NASDAQ: MGRX), an up-and-coming Nasdaq small-cap launching disruptive products and services focused on the rapidly growing $31 billion men’s health and wellness marketplace.
The company’s co-founder and CEO, Jacob Cohen, was interviewed last week on the popular McNallie Money YouTube podcast. It’s worth checking out.
The interview segment does an excellent job of providing an in-depth sense of where this story is heading, and Mr. Cohen knocks it out of the park in terms of capturing why MGRX is such an interesting small-ca ..read more
Wall Street PR
2M ago
The Men’s Health Industry sets up as one of the most attractive growth market niches in the current bull market for several reasons.
Most importantly, it is a huge premise that has simply failed to cohere in recent cycles likely because of unconscious biases preventing most people from accepting the notion that men represent a target market worth approaching.
It’s a bit like fish struggling to see water or the painter failing to see the canvas. In a traditionally patriarchal social system, the last people you notice as a special interest group are the men. This shouldn’t be a controversial ide ..read more
Wall Street PR
2M ago
Equities continue to shrug off anything the world throws at them as we sit on the precipice of huge technological breakthroughs in energy, biotech, AI, and other fields. The wall of worry is in place, and it’s functioning as a nice ramp for stocks to climb.
But investors looking for bargains face the age-old problem: how do you find value once the bull has left the barn?
Today’s piece is a straightforward exercise in proving to you that it’s still possible. Our case in point: Nascent Biotech Inc. (OTCMKTS:NBIO), an early-stage biotech with a pipeline now reaching phase 2 for the first time. Th ..read more
Wall Street PR
6M ago
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Viper Energy, Inc. (NASDAQ: VNOM) announces a Secondary Offering of 11.5 million shares of its Class A common stock by its parent company, Diamondback Energy, Inc., with expected gross proceeds of $402.5 million. The offering is managed by top financial institutions and includes an option for additional shares. The Secondary Offering is set to close on March 8, 2024.
The announcement by Viper Energy, Inc. of a secondary public offering of 11,500,000 shares by its parent company, Diamondback Energy, Inc., is a significant event that w ..read more
Wall Street PR
6M ago
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
SoFi Technologies, Inc. announces pricing of $750 million convertible senior notes due 2029 in a private offering to qualified institutional buyers.
The issuance of $750 million in 1.25% convertible senior notes due 2029 by SoFi Technologies, Inc. represents a significant capital-raising activity that warrants attention from investors and market analysts. Convertible notes are a form of debt that can be converted into equity, typically stock, at a later date under specified conditions, which can dilute existing shareholders but also ..read more
Wall Street PR
6M ago
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Akero Therapeutics, Inc. (AKRO) announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at $29.00 per share, aiming to raise $319.0 million. The company has also granted underwriters an option to purchase additional shares. This move is part of Akero’s strategy to develop treatments for metabolic diseases.
Positive
Akero Therapeutics announced a public offering of 11,000,000 shares of common stock at $29.00 per share.
The gross proceeds from the offering are expected to be $319.0 million.
Und ..read more